August 16, 2025

Discovery of Cell-Permeable Macrocyclic Cyclin A/B RxL Inhibitors that Demonstrate Anti-tumor Activity in E2F-Driven Cancers.

Key Points

Lead compound 34 reduced tumor growth significantly in E2F-driven cancer models, indicating potential efficacy.
Inhibition of the Cyclin A/E2F binding presents a novel approach compared to traditional CDK inhibitors.
New macrocyclic inhibitors were developed using structure-based design, demonstrating selectivity against RB1/E2F dysregulated cells.
Further studies are needed to validate these findings in clinical settings and assess long-term effects.

Abstract

The cyclin-dependent kinase (CDK)/retinoblastoma protein (RB)/early region 2 binding factor (E2F) axis forms the core transcriptional machinery driving cell cycle progression. Alterations in RB1 or other pathway members occur in many cancers, resulting in heightened oncogenic E2F activity. The activity of E2F is regulated by RxL-mediated binding to the hydrophobic patch (HP) of Cyclin A; blocking this interaction results in the hyperactivation of E2F and synthetic lethality in E2F-driven tumors. While mechanistically differentiated and potentially more selective than blocking CDK activity (e.g., CDK2 or CDK4 inhibitors), the Cyclin A/E2F RxL interaction was deemed undruggable. Utilizing structure-based design, we have discovered a family of cell-permeable macrocyclic Cyclin A/B RxL inhibitors that show potent and selective activity against RB1/E2F-dysregulated cancer cell lines. Lead compound 34 demonstrated proof-of-concept efficacy via intraperiotoneal (IP) administration in mouse cell line-derived xenograft (CDX) tumor models.

Mark Helpful

Bookmark

Relay